Amyris (NASDAQ:AMRS) and Aemetis (NASDAQ:AMTX) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.
This table compares Amyris and Aemetis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Amyris and Aemetis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amyris presently has a consensus target price of $9.67, indicating a potential upside of 16.19%. Aemetis has a consensus target price of $2.00, indicating a potential upside of 90.48%. Given Aemetis’ higher possible upside, analysts clearly believe Aemetis is more favorable than Amyris.
Institutional and Insider Ownership
27.9% of Amyris shares are owned by institutional investors. Comparatively, 17.2% of Aemetis shares are owned by institutional investors. 21.8% of Amyris shares are owned by insiders. Comparatively, 24.2% of Aemetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Amyris and Aemetis’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amyris||$143.45 million||2.92||-$72.32 million||($3.05)||-2.73|
|Aemetis||$150.15 million||0.14||-$30.30 million||N/A||N/A|
Aemetis has higher revenue and earnings than Amyris.
Risk & Volatility
Amyris has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Aemetis has a beta of -0.82, suggesting that its share price is 182% less volatile than the S&P 500.
Aemetis beats Amyris on 6 of the 11 factors compared between the two stocks.
Amyris Company Profile
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Aemetis Company Profile
Aemetis, Inc. operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced bio refineries. It owns and operates an ethanol plant in the California Central Valley near Modesto; and a biodiesel plant in Kakinada, India. The company sells biodiesel and refined glycerin to resellers, distributors, and refiners through its sales force and independent sales agents, as well as to brokers who resell the product to end-users. It also produces ethanol; and wet distiller's grains, distiller's corn oil, and condensed distillers soluble or corn syrup products to dairies and feedlots as animal feed. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.